On October 4, Eli Lilly and Company announced changes in its senior leadership team on its official website. Michael Mason, Executive Vice President and President of Eli Lilly's Diabetes and Obesity Division, will retire at the end of 2023.
Patrik Jonsson will serve as Executive Vice President and President of Eli Lilly's Diabetes and Obesity Division, as well as Executive Vice President and President of Eli Lilly USA, effective January 1, 2024.
Daniel Skovronsky, Chief Scientific Officer of Eli Lilly and Company and President of Eli Lilly Research Laboratories, will succeed Jonsson as President of Immunology at Eli Lilly and Company.
In addition, Eli Lilly and Company announced that Leigh Ann Pusey, Executive Vice President of Corporate Affairs and Communications, has decided to leave the company at the end of 2023 to return to Washington, D.C. to pursue other career opportunities.